10.6084/m9.figshare.11336849.v1
Lifeng Mu
Lifeng
Mu
Benhong Zhou
Benhong
Zhou
Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
Adis Journals
2020
Alectinib
China
Cost-Effectiveness
Non-Small Cell Lung Cancer
Oncology
2020-01-02 15:49:58
Figure
https://adisjournals.figshare.com/articles/figure/Letter_Cost-Effectiveness_of_Alectinib_for_Patients_with_Untreated_ALK-Positive_Non-Small_Cell_Lung_Cancer_in_China/11336849
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>